Farxiga vs Lantus Side Effects: What Women Need to Know Before Choosing

How These Two Drugs Actually Work (and Why That Shapes Every Side Effect)

Farxiga and Lantus are not competing versions of the same drug. They work through entirely different biology, which is why comparing their side-effect profiles requires understanding the mechanism first.

Dapagliflozin (Farxiga) blocks the SGLT2 transporter in your kidneys, forcing your body to excrete glucose in your urine rather than reabsorbing it. About 70 to 90 grams of glucose leave your body through urine every day on a standard 10 mg dose, which lowers blood sugar without triggering insulin release. Because glucose exits through the urinary tract, the genital and urinary area becomes a predictably higher-risk zone for infection.

Insulin glargine (Lantus) is a modified form of human insulin designed to dissolve slowly under the skin after injection, releasing a steady, low level of insulin over approximately 24 hours. It works the way your pancreas should work overnight. The risks that follow from this mechanism are low blood sugar (if the dose is too high or you skip a meal) and the metabolic effects of insulin itself, including fluid retention and fat storage.

Knowing this, most of the side-effect differences below are logical extensions of the mechanism, not random drug quirks.

Side-Effect Profile: Farxiga

Genital Yeast Infections and UTIs

This is the most clinically significant women's-health concern with dapagliflozin. The sugar-rich urine the drug creates is an excellent growth medium for Candida species. In pooled clinical trial data, genital mycotic infections occurred in approximately 8 to 9% of women taking dapagliflozin 10 mg, compared with roughly 1 to 2% of women on placebo. That is a real and meaningful difference.

Urinary tract infections also occur at a slightly higher rate, though the absolute increase is smaller than for yeast infections.

Women who are already prone to recurrent vulvovaginal candidiasis, women with poorly controlled blood sugar, and women in perimenopause (where declining estrogen already thins vaginal tissue and shifts the vaginal microbiome) face compounded risk. If you have had three or more yeast infections in a year, discuss this honestly with your clinician before starting Farxiga.

Genital Hygiene and Fournier's Gangrene

A rare but serious risk: necrotizing fasciitis of the perineum (Fournier's gangrene) carries an FDA black-box warning for all SGLT2 inhibitors. Cases are rare, but women should report any genital pain, swelling, redness, or fever immediately.

Diabetic Ketoacidosis (DKA)

SGLT2 inhibitors can cause euglycemic DKA, meaning DKA with a blood sugar that looks only mildly elevated or even normal. The FDA added a warning in 2015 after reports emerged across the SGLT2 inhibitor class. This risk is highest in type 1 diabetes (Farxiga is approved for type 1 as an adjunct to insulin), during prolonged fasting, during illness, and in the perioperative period. Women with type 1 diabetes on Farxiga need a clear plan for sick-day management.

Volume Depletion and Blood Pressure

Losing 70 to 90 grams of glucose in urine daily also means losing osmotic water. Dapagliflozin produces a mild diuretic effect. In the DECLARE-TIMI 58 trial, dapagliflozin reduced systolic blood pressure by approximately 2 to 3 mmHg compared with placebo. This can be a benefit if you have hypertension, but it may cause dizziness on standing, particularly in older women or women already on diuretics or ACE inhibitors.

Weight

Farxiga produces a modest but consistent weight reduction. Across trials, the average weight loss is 2 to 3 kg (roughly 4 to 6 pounds) over 24 weeks. For women with obesity-related type 2 diabetes, PCOS, or cardiometabolic disease, this is frequently a therapeutic advantage rather than a side effect.

Bone Fracture Risk

Early pooled analyses raised concern about increased fracture risk with dapagliflozin. The signal has not been as consistent as with canagliflozin, but women already at elevated osteoporosis risk (postmenopausal status, low body weight, prior fragility fracture) should have this discussed as part of the risk-benefit conversation.

Side-Effect Profile: Lantus

Hypoglycemia

This is the most common and most serious day-to-day risk with insulin glargine. In the ORIGIN trial, which enrolled 12,537 people with dysglycemia or early type 2 diabetes, the rate of severe hypoglycemia was 1.00 events per 100 person-years in the insulin glargine group vs 0.31 in the standard-care group. That threefold increase is clinically meaningful.

For women, hypoglycemia risk is not uniform across the menstrual cycle. Insulin sensitivity increases in the follicular phase and declines in the luteal phase as progesterone rises. Women using Lantus may notice they need slightly different doses at different points in their cycle. This is real physiology, not inconsistency in your behavior, and it is largely absent from the standard patient education that accompanies insulin prescribing.

Weight Gain

Insulin promotes glucose storage as glycogen and fat. In the ORIGIN trial, participants in the insulin glargine group gained a mean of 1.6 kg over 6.2 years of follow-up, while the standard-care group lost 0.5 kg. The net difference was approximately 2.1 kg. This may seem small in absolute terms, but for women already managing weight-related metabolic disease or perimenopausal weight redistribution, the direction of effect matters.

Injection-Site Reactions

Lipohypertrophy (fatty lumps under the skin at injection sites) develops in up to 30 to 50% of long-term insulin users who do not rotate sites properly. Bruising, redness, and mild soreness are common early on.

Edema and Cardiovascular Fluid Shifts

Insulin causes renal sodium retention. Peripheral edema (swelling in the legs or feet) is a recognized side effect, especially at higher doses. Women with heart failure, chronic kidney disease, or venous insufficiency should be monitored.

Allergic Reactions

True insulin allergy is rare with modern analogs like glargine, but localized skin reactions at the injection site affect a minority of users. Systemic allergic reactions are very uncommon.

Head-to-Head: What the Major Trials Tell Us

No single trial has directly randomized women to Farxiga versus Lantus and measured side effects head-to-head. The comparison here is synthesized from separate large trials, and that limitation matters.

DAPA-HF (2019)

The DAPA-HF trial enrolled 4,744 adults with heart failure with reduced ejection fraction (HFrEF) and randomized them to dapagliflozin 10 mg daily vs placebo. The primary outcome, a composite of worsening heart failure or cardiovascular death, was reduced by 26% with dapagliflozin (hazard ratio 0.74, 95% CI 0.65 to 0.85). Women made up only 23% of the enrolled population, which limits sex-specific inference, and this is an evidence gap you should know about.

The DAPA-HF trial was not primarily a side-effect comparison study, but it confirmed that the tolerability profile of dapagliflozin in a high-risk cardiac population was acceptable, with genital mycotic infections being the most distinguishing adverse event versus placebo.

ORIGIN (2012)

The ORIGIN trial tested whether early basal insulin therapy in people with cardiovascular risk and impaired fasting glucose, impaired glucose tolerance, or early type 2 diabetes would reduce cardiovascular outcomes. After a median follow-up of 6.2 years, cardiovascular outcomes were neutral (hazard ratio for CV death, nonfatal MI, or nonfatal stroke: 1.02, 95% CI 0.94 to 1.11). Insulin glargine did not reduce or increase major cardiovascular events in this population. Hypoglycemia and weight gain were the confirmed safety signals.

The ORIGIN trial enrolled approximately 35% women, a better representation than many cardiac trials, though still not equal.

Women-Specific Conditions: PCOS, Perimenopause, and Thyroid

PCOS

PCOS is fundamentally a condition of insulin resistance. Women with PCOS have a two- to fourfold increased risk of type 2 diabetes compared with women without the condition. Both drugs can be used in PCOS with type 2 diabetes, but their metabolic profiles differ in important ways.

Dapagliflozin reduces insulin levels by lowering blood glucose without stimulating insulin secretion. Lower circulating insulin may reduce ovarian androgen production, since excess insulin drives testosterone synthesis in the ovarian stroma. A small number of studies have examined SGLT2 inhibitors in PCOS specifically, and while the data are preliminary, the mechanism is plausible. Metformin remains the first-line insulin sensitizer for PCOS, but dapagliflozin may have a role as add-on therapy in women with PCOS and established type 2 diabetes or cardiovascular risk.

Lantus, by contrast, raises circulating insulin levels. For a woman with PCOS who already has hyperinsulinemia, adding exogenous basal insulin may theoretically worsen androgen-driven symptoms (acne, hirsutism, cycle irregularity), though this is not well-studied and Lantus may be necessary when beta-cell function is insufficient.

Perimenopause

Perimenopause brings estrogen fluctuation and eventual decline, which reduces insulin sensitivity and shifts fat toward the abdomen. This makes metabolic management more complex.

The genital yeast infection risk of Farxiga is compounded in perimenopause. Declining estrogen thins the vaginal epithelium and reduces Lactobacillus dominance, making the vulvovaginal environment more susceptible to candida overgrowth. If you are perimenopausal and have recurrent vaginal symptoms, weigh this carefully.

Lantus-associated weight gain may be more problematic in perimenopause because the hormonal environment already promotes adiposity. Monitoring and dose optimization become especially important during this transition.

Thyroid and Adrenal Function

Neither dapagliflozin nor insulin glargine directly affects thyroid or adrenal hormone levels. Women with untreated hypothyroidism have impaired glucose metabolism and altered insulin sensitivity; treating the thyroid condition first is usually the priority before adding either diabetes medication.

Pregnancy, Lactation, and Contraception

This section is required for every drug article on WomanRx. Read it carefully regardless of your current reproductive plans.

Farxiga (Dapagliflozin)

Pregnancy: Contraindicated in the second and third trimesters. The FDA labeling for dapagliflozin states that the drug should be discontinued when pregnancy is confirmed, because SGLT2 inhibitors affect renal development in animal studies during a period corresponding to the second and third trimesters in humans. First-trimester human data are limited. The drug should be considered contraindicated throughout pregnancy until more human data exist.

If you are a woman of reproductive age taking Farxiga and not using reliable contraception, discuss this with your clinician. An unplanned pregnancy while on Farxiga requires immediate medical review.

Lactation: Dapagliflozin is present in rat milk, and the manufacturer recommends against use during breastfeeding because the effect on the developing kidney of a nursing infant is unknown.

Contraception requirement: If you are using Farxiga and could become pregnant, use effective contraception. Farxiga is not a teratogen in the same category as thalidomide or isotretinoin, but the second- and third-trimester renal risk is serious enough that unplanned pregnancy is a real hazard.

Lantus (Insulin Glargine)

Pregnancy: Preferred basal insulin for gestational and preexisting diabetes. Insulin does not cross the placenta in clinically significant amounts. ACOG Practice Bulletin 201 (2018, reaffirmed 2023) states that insulin is the preferred pharmacologic agent for managing diabetes in pregnancy, and insulin glargine has an established and generally reassuring safety record in pregnancy, though NPH insulin remains the only basal insulin with the most extensive prospective human data.

Lactation: Insulin glargine is compatible with breastfeeding. Insulin is a large protein molecule that does not transfer into breast milk in meaningful amounts, and any small amount would be digested in the infant's gastrointestinal tract.

Dose adjustments in pregnancy: Insulin requirements increase substantially across pregnancy, often doubling or tripling by the third trimester. Women with preexisting type 1 or type 2 diabetes on Lantus will need frequent dose adjustments throughout pregnancy and should be managed in collaboration with maternal-fetal medicine.

Who Should Consider Farxiga vs Lantus: A Life-Stage Guide

The choice between these two drugs is rarely binary. Most women with type 2 diabetes use multiple agents. But if you are deciding which direction to add or which to prioritize, here is a practical framework organized by life stage and condition.

Reproductive Years, Not Trying to Conceive

Farxiga may be appropriate if you have type 2 diabetes with cardiovascular risk, heart failure, or chronic kidney disease, and you are using reliable contraception. The weight-neutral to weight-loss effect is often preferred. Monitor for recurrent yeast infections.

Lantus becomes more appropriate if oral and non-insulin agents have failed to achieve glycemic targets, or if you have type 1 diabetes requiring basal-bolus therapy.

Trying to Conceive

Discontinue Farxiga before attempting conception and switch to insulin-based regimens. Lantus is an acceptable basal insulin during conception attempts. Work with your endocrinologist and OB-GYN to optimize blood sugar before conception, since preconception A1C below 6.5% significantly reduces the risk of neural tube defects and congenital heart disease.

Pregnancy

Farxiga: stop immediately. Lantus: continue with dose adjustments under specialist supervision.

Postpartum and Lactation

Farxiga should not be used while breastfeeding based on current labeling. Lantus is safe during lactation. Postpartum insulin requirements drop sharply in the first days after delivery; close monitoring is needed to prevent hypoglycemia.

Perimenopause

Both drugs carry specific considerations outlined above. Farxiga's weight-loss effect may be welcome, but genital infection risk in the context of vaginal atrophy warrants honest discussion. Lantus-associated weight gain compounds perimenopausal metabolic change.

Post-Menopause

Fracture risk with dapagliflozin and bone density should be assessed in postmenopausal women before prescribing, particularly if they have other osteoporosis risk factors. Lantus-associated hypoglycemia is more dangerous in older women who may have hypoglycemia unawareness or fall risk.

Evidence Gaps: What We Still Do Not Know in Women

Women have been systematically underrepresented in the large cardiometabolic trials that form the evidence base for both drugs. The DAPA-HF trial enrolled only 23% women, and sex-stratified analyses for side-effect outcomes were not the primary design aim. The ORIGIN trial enrolled approximately 35% women.

What this means for you: the genital infection data for dapagliflozin in women comes largely from smaller phase III trials and pooled regulatory submissions, not from large independent women-health trials. The cycle-phase variation in insulin requirements with Lantus has been described in physiological studies but has not been systematically tracked in large randomized trials. Both gaps are real, and clinicians who tell you otherwise are overstating the evidence.

WomanRx editorial policy is to name evidence gaps rather than smooth over them. The data we have are sufficient to make reasonable clinical decisions, but they are not sufficient to claim perfect precision in predicting how either drug will behave for an individual woman across her full hormonal life.

Switching Between Farxiga and Lantus

Switching from Farxiga to Lantus (or vice versa) is not a simple substitution. They treat overlapping targets through different mechanisms, and any switch requires recalibrating glycemic monitoring.

If you are moving from Farxiga to Lantus, your clinician will typically start with a conservative basal insulin dose (often 10 units or 0.1 to 0.2 units per kilogram) and titrate based on fasting glucose readings. You will need to monitor for hypoglycemia carefully in the first weeks.

If you are moving from Lantus to Farxiga (for example, because you are stable in type 2 diabetes and want to reduce injection burden or lose weight), your insulin will usually be tapered gradually, not stopped abruptly. Abrupt cessation of basal insulin in type 1 diabetes is dangerous and should never be done.

The decision to switch should be driven by your glycemic data, your side-effect history, your cardiovascular risk profile, and your life stage, not by cost alone, though cost is a legitimate and important factor worth discussing openly with your clinician.

Drug Interactions and Practical Monitoring

Farxiga interactions to know: Diuretics (increased dehydration risk), other glucose-lowering agents (additive hypoglycemia risk if insulin or sulfonylureas are co-prescribed), and rifampin (reduces dapagliflozin exposure by about 22%).

Lantus interactions to know: Any drug that affects insulin sensitivity (corticosteroids raise blood sugar and increase insulin requirements; beta-blockers can mask hypoglycemia symptoms; alcohol potentiates hypoglycemia).

Monitoring for Farxiga: Renal function (eGFR) before and periodically during treatment. Farxiga is not recommended if eGFR is persistently <25 mL/min/1.73 m² for its glucose-lowering indication, though it retains heart failure and kidney protection indications at lower eGFR levels. Urine glucose is expected to be positive and is not a sign of infection. Genital symptoms should be assessed at each visit.

Monitoring for Lantus: Fasting blood glucose daily, A1C every 3 months until stable then every 6 months, injection site rotation, weight, and signs of hypoglycemia (shakiness, sweating, confusion, rapid heartbeat).